Subscribe to Newsletter

Standards & Regulation

Manufacture Small Molecules

Making Your Mark

| Jim Gastle, Grant Peters | 4 min read

US-based law and patenting experts offer their thoughts on IP protection in the digital age

Manufacture Small Molecules

The Contaminated Childrens’ Cough Syrup Scandal

| Stephanie Vine | 4 min read

I explore recent cases of pediatric cough medicines contaminated with diethylene glycol.

Business & Regulation Standards & Regulation

Why Are Some Medicines Linked to Suicide?

| Stephanie Vine | 3 min read

The EMA is reviewing whether certain Novo Nordisk drugs are linked to suicidal thoughts

Discovery & Development Drug Discovery

A Call to Arms for Antimicrobial Resistance

| Peter Jackson | 13 min read

Investment into new antimicrobial therapies has been lacking for decades – and now we’re now paying the price.

Business & Regulation Business Practice

Never Break the Chain

| Nadine Lampka | 5 min read

How do we prevent criminals from reusing primary packaging for counterfeit medicines? Labeling solutions and other creative concepts can help.

Business & Regulation Standards & Regulation

MSD Files Lawsuit Against US Government

| Stephanie Vine | 4 min read

MSD describes drug price negotiation program as “sham” and “tantamount to extortion”

Business & Regulation Standards & Regulation

FDA Warning Letters: May 2023 Edition

| Stephanie Vine | 4 min read

Misbranded drugs, unapproved drugs, and companies who don’t know that ophthalmic drugs should be manufactured in a sterile environment…

Manufacture Packaging

Blisters of Mercy

| 7 min read

Child exposure to pharmaceutical substances appears to be decreasing, but what more can packaging companies do to push the trend?

Business & Regulation Digital Technologies

Entering the Modern Era for Data-Driven Quality Control

| Jason Boyd, Simon Meffan-Main | 4 min read

A new class of modern cloud systems promises the next step change in QC productivity and data integrity.

Business & Regulation Business Practice

Here Come the Humira Biosimilars

| Stephanie Vine | 2 min read

The first Humira biosimilar in the US is here, but market penetration could be a challenge.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register